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ABSTRACT
Inappropriate antimicrobial treatment (deﬁned as use of antimicrobial agent to which a pathogen is
resistant) or a delay in starting appropriate treatment are both associated with increased morbidity and
mortality. Studies of ventilator-associated pneumonia, intra-abdominal infections or bacteraemia
document higher mortality in patients who received inappropriate therapy. In addition, the outcome
in patients switched from inappropriate to appropriate therapy is better than for patients who remained
on inappropriate therapy, but the beneﬁt is not as great as for those who were started on appropriate
therapy initially. While inappropriate therapy undoubtedly has an important inﬂuence on outcomes, it
needs to be considered in the context of other patient risk-factors, such as co-morbid conditions, severity
score measures, and functional status. When assessing the impact of inappropriate therapy on outcomes
such as length of hospital stay, it is important to be as precise as possible about the time of onset of
infection. Failure to do so may lead to inaccurate estimation of the effect of inappropriate therapy. While
the likelihood that resistant pathogens can increase costs throughout the healthcare system is generally
recognised, an under-appreciated aspect of resistance is its consequences for patients and their carers.
Initiatives are underway to gauge the impact of resistance and strategies to combat its spread.
Keywords Antibacterial agents, cost, nosocomial infection, outcome assessment, review, ventilator-
associated pneumonia
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INTRODUCTION
The dictionary deﬁnition of ‘appropriate’ is ‘suit-
able or right for a particular situation or occasion’.
Therefore, inappropriate treatment encompasses
the wrong choice of antibiotic or use of an agent to
which the pathogen is resistant. This deﬁnition
therefore includes excessive treatment in addition
to inadequate treatment. Inappropriate antimicro-
bial therapy is associated with increased mortality
in bacteraemia, peritonitis, and ventilator-associ-
ated pneumonia (VAP). In addition, it has conse-
quences for the healthcare system and effects on
patients, and their carers and families. This review
will focus on the wide-ranging impact of one type
of inappropriate therapy, namely use of an agent
to which the pathogen is resistant, and the effects
of delays in initiating appropriate treatment.
IMPACT OF INAPPROPRIATE
TREATMENT
Evaluating the consequences of inappropriate
treatment in a randomised, double-blind trial
would be unethical. However, observational stud-
ies do allow insight into its impact. One such
study was conducted by Luna et al. [1], who
compared two treatment approaches in 132
patients exhibiting symptoms of VAP. In one
approach, antimicrobials were administered only
after the diagnosis of pneumonia had been con-
ﬁrmed microbiologically by bronchoscopy with
bronchoalveolar lavage (BAL). In the second
approach, empirical antimicrobial treatment was
given as soon as a clinical diagnosis of VAP was
made. The study examined the adequacy of
coverage at three time-points: prior to BAL;
post-BAL, or when culture results were available.
The results revealed that when antimicrobial
therapy was initiated before BAL, the mortality
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rate was lower when the drug matched the
pathogen (i.e., appropriate therapy) than when
the drug did not match the pathogen (i.e.,
inappropriate therapy). If treatment with an
appropriate drug was delayed until post-BAL or
until culture results were available, mortality rates
were higher in both of these groups than in the
group that received appropriate treatment from
the beginning. These results show that timely
administration of appropriate antimicrobial treat-
ment can improve survival in patients with VAP.
Moreover, while patients in the study who were
switched to appropriate antibiotics after culture
results were available did better than patients who
remained on inappropriate therapy, the outcome
was not as good as for those who started on
appropriate antibiotics from the beginning.
Thebeneﬁt of early, appropriate treatment is also
illustrated by Mosdell et al. [2], who conducted a
retrospective chart review of 480 patients with
secondary bacterial peritonitis. In that study, out-
comes were compared for patients who received
appropriate therapy based on culture data from
samples obtained intra-operatively and patients
who received inappropriate therapy. Patients who
received empirical treatment with an appropriate
antimicrobial agent at the time of surgery had
fewer wound infections (14.4% vs. 26.5%),
abscesses (10.5% vs. 34.7%), re-operations (13.9%
vs. 36.7%), and other complications (18.9% vs.
51.0%), aswell as lowermortality (5.6%vs. 12.2%),
than thosewho received an empirical antimicrobial
agent with inadequate coverage. This study is
important not only because it highlights the impor-
tance of appropriate therapy in improving out-
comes, but also because it shows that appropriate
treatment is only one ofmany factors that inﬂuence
outcomes. In this study, about one patient in ﬁve
developed complications despite appropriate anti-
biotic administration, and half the patients got
better even though they received an inappropriate
antibiotic.
Although neither of these studies by Luna et al.
or Mosdell et al. was a prospective randomised
trial, both suggest that the timing of antimicrobial
treatment is important. Treating only after the
microbiological test results are obtained ensures
that the correct antimicrobial is chosen, but this
strategy increases the risk of a worse outcome due
to delayed treatment. Changing to the right
antibiotic once the culture results come back is
not as beneﬁcial as getting the antibiotic right
from the start, possibly because of physiological
deterioration of the patient or because of bacterial
dissemination or abscesses, which are difﬁcult to
treat with antibiotics.
In a prospective cohort study of 492 critically ill
patients [3] admitted to the intensive care unit
(ICU) with a bloodstream infection, inadequate
antimicrobial treatment proved to be the most
important risk-factor for in-hospital mortality. In
this study, inappropriate treatment was deﬁned
as: the microbiological documentation of infec-
tion, such as a positive blood culture result, that
was not effectively treated at the time when the
causative pathogen was known; or the absence of
antimicrobial therapy directed at a likely class of
microorganisms (e.g., absence of therapy for
Candida); or the administration of an antimicrobial
to which the pathogen responsible for the infec-
tion was resistant (e.g., empirical treatment with
oxacillin for bacteraemia subsequently attributed
to methicillin-resistant Staphylococcus aureus
(MRSA) on the basis of blood culture results).
The mortality rate for patients who initially
received inappropriate antimicrobial treatment
(61.9%) was signiﬁcantly greater than the rate
for patients who received antimicrobial treatment
that matched the pathogen from the start (28.4%;
p < 0.001).
In addition to illustrating the impact of inap-
propriate treatment on mortality rates, this study
also provides useful information on hospital
mortality rates according to causative pathogen
(Fig. 1) [3]. The hospital mortality rate showed a
Fig. 1. Inappropriate antimicrobial treatment and mortal-
ity rates with common bloodstream infection pathogens.
Reproduced with permission from Ibrahim et al. [3]. CNS,
coagulase-negative staphylococci; MRSA, methicillin-sen-
sitive Staphylococcus aureus; MSSA, methicillin-sensitive
S. aureus; VRE, vancomycin-resistant enterococci; E. coli,
Escherichia coli; P. aeruginosa, Pseudomonas aeruginosa.
16 Clinical Microbiology and Infection, Volume 14, Supplement 3, April 2008
 2008 The Authors
Journal Compilation European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 3), 15–21
statistically signiﬁcant relationship to the rate of
inappropriate treatment for individual micro-
organisms (Spearman correlation coefﬁcient =
0.8287; p 0.006). However, despite low rates of
inappropriate treatment for methicillin-sensitive
S. aureus (MSSA) infection or Escherichia coli infec-
tion, the mortality associated with these infections
was nearly as high as that for infections due to
resistant organisms. This further indicates that
inappropriate therapy is not the only factor
determining mortality. Factors such as patient
status and pre-morbid conditions also affect
patient outcome.
Lodise et al. [4] studied the effect of delayed
appropriate treatment on clinical outcomes in
patients with S. aureus bacteraemia who had
differing levels of risk-factors. They ﬁrst identi-
ﬁed the breakpoint for infection-related mortality
according to the time from when patients received
antimicrobial therapy (Fig. 2). The time break-
point that maximised the difference in infection-
related mortality overall was 44.75 h, which
served to deﬁne treatment given <44.75 h after
S. aureus identiﬁcation as early treatment, and
treatment after 44.75 h as delayed treatment.
Infection-related mortality for the early-treatment
group was 19.3% and that for the delayed-
treatment group was 33.3% (p 0.05).
To evaluate the importance of other patient
risk-factors for outcomes, the investigators as-
sessed whether the impact of delaying treatment
was the same for severely ill as for lower-risk
patients. They used the Acute Physiology and
Chronic Health Evaluations (APACHE II) scoring
method to measure risk. An APACHE II score
‡15.5 maximised the difference in the infection-
related mortality, providing a dividing point
between high-risk and low-risk patients (Fig. 2).
The group with an APACHE II score <15.5 had
the lowest risk of mortality (6.7%), and no
signiﬁcant difference in outcomes was observed
between delayed treatment (3.8%) and early
treatment (7.8%). In the group with an APA-
CHE II score ‡15.5 and high-risk sources of
infection (e.g., osteoarticular infection, skin and
soft-tissue infection, or pressure ulcer), the mor-
tality rate was very high (56.6%), and was
signiﬁcantly higher in the delayed-treatment
group than in the early-treatment group (86.7%
vs. 44.7%, respectively). In patients with an
APACHE II score ‡15.5 but no high-risk sources
of infection, the mortality rate was high (12.5%)
and the difference between delayed treatment
(28.6% mortality) and early treatment (5.9%
mortality) was marked. Therefore, it is important
to relate the consequences of delayed treatment to
individual patients and their risk-factors.
Leibovici et al. [5] have also analysed the risk-
factors for mortality. In this study, inappropriate
treatment was one of several risk-factors associ-
ated with increased likelihood of death in a
logistic regression model. The odds ratio for
fatality in a patient given inappropriate treatment
was 1.6, and the effect was independent of other
risk-factors, which included older age, congestive
heart failure, corticosteroid treatment, prior anti-
biotic treatment, endotracheal intubation, neutro-
penia, and septic shock (Fig. 3). Thus, it is crucial
to consider the inappropriate or delayed antibiotic
therapy in the context of these other risk-factors.
As described above, inappropriate therapy is
associated with negative outcomes in terms of
mortality. It is difﬁcult to determine the preva-
lence of inappropriate therapy, as the rates
Fig. 2. Classiﬁcation and regression
tree (CART) analysis of predictors
of infection-related mortality in
Staphylococcus aureus bacteraemia.
Reproduced with permission from
Lodise et al. [4]. APACHE II, acute
physiology and chronic health
evaluation; D-Tx, delayed treatment;
E-Tx, early treatment; SAB, S. aureus
bacteraemia.
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reported in the literature vary widely among
studies [3,4,6,7] (Table 1). Nevertheless, on the
basis of these studies, it appears to be common.
Given the signiﬁcant consequences of inappro-
priate therapy and its prevalence, efforts should
be made to ensure that appropriate antibiotic
therapy is undertaken in order to improve out-
comes. An approach that may guide therapy is the
use of computerised decision-support systems.
These are being developed to direct the physician
in antimicrobial choice and timing; TREAT is one
such system that has been evaluated in a clinical
setting [8]. It is a based on a causal probabilistic
network, where known causal relationships
between the risk-factors put into the system and
the magnitude of their outcomes are used to
determine therapeutic recommendations. In a
study with a cluster randomised trial design,
hospital wards that used TREAT prescribed
appropriate empirical treatment signiﬁcantly
more frequently than wards that did not. This
was despite the fact that only half of the physicians
in the intervention arm used the support system.
Wards using the system had statistically signiﬁ-
cant reductions in antimicrobial costs [8]. Mortal-
ity and length-of-stay outcomes were lower in
wards using TREAT than in those not using it, but
the difference was not statistically signiﬁcant
(Table 2). Therefore, tools such as TREAT hold
promise because they could become a useful guide
to the physician and may eventually help increase
the rate of appropriate empirical treatment and
improve outcomes. The TREAT system has been
Fig. 3. Odds ratio of fatality related to inappropriate
empiricaltreatment and other demographic, physiological
and microbiological risk-factors [5].
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made available as a commercial product, but it is
unlikely that hospitals will be prepared to make
the necessary ﬁnancial and time commitments
without further evidence of cost-effectiveness.
INAPPROPRIATE TREATMENT AND
RESISTANCE-RELATED COSTS
Inappropriate antimicrobial treatment has nega-
tive effects beyond increased rates of mortality
and morbidity. Treatment failures can require
extra hospital days, additional laboratory costs,
and costly isolation and other infection control
measures [9], and may affect subsequent empir-
ical antibiotic choices, resulting in higher drug
costs. Additional costs also stem from the need to
develop new antimicrobial agents and to imple-
ment educational programmes on antimicrobial
resistance [10].
The increase in costs that accompany the
detection of resistant organisms is illustrated by
an outbreak of infection with penicillin-resistant
Streptococcus pneumoniae in a hospital for the
elderly. Ten cases of penicillin-resistant
S. pneumoniae were detected, and this led to a
change in antibiotic policy. The mean monthly
antibiotic cost for the period preceding the detec-
tion of the resistant strain was approximately
£2900 (cost in 1994). This more than doubled to
about £7400 in the month when the resistant
strain was detected, reﬂecting the fact that pen-
icillin was largely replaced by cefotaxime as a
precaution to stem the emergence of further
resistant cases [11]. The costs fell over subsequent
months but remained higher than before the
resistant pathogens were detected.
To evaluate outcomes, reliable and accurate
data are necessary. The data should be collected
so as to take the time-dependency of the event
that leads to the outcome into account. A study by
Blot et al.[12] that assessed mortality rates in
patients with bacteraemia involving MRSA and
MSSA illustrates the importance of considering
the time to an event. The attributable mortality
rate for MRSA was approximately 22% higher
than that for MSSA. However, mortality rates did
not differ in the ﬁrst few weeks of ICU stay, and
the difference was only apparent after 35 days.
Once patients developed MRSA bacteraemia
(20 days vs. 8 days for MSSA bacteraemia), the
differences in outcome became greater with
increasing ICU and hospital stay.
Mathematical models are being developed that
incorporate time-dependent variables. One such
model, called ChangeLOS [13], is being devel-
oped to account for timing of events when
determining the effect of a complication on length
of stay (LOS). It allows multistate systems to be
described and can determine the probabilities of
transition between these states. In turn, this
allows the timing of events to be incorporated
into outcomes analysis.
The ChangeLOS model has been applied to
assess the extent to which nosocomial pneumonia
affects LOS. Using data from an 18-month cohort
in ﬁve ICUs, the model computed that nosocomial
pneumonia prolongs LOS by an average of
6.2 days [14]. In contrast, a traditional matched
analysis of the data (i.e., comparison between
infected and non-infected patients) overestimated
the effect of nosocomial infection by a factor of
more than two. This is because matched analysis
incorrectly treats nosocomial infection as a base-
line covariant, whereas it needs to be considered
as a time-dependent variable. Therefore, accu-
rately deﬁning the relationship between an event
(e.g., infection) and an outcome (e.g., death or
LOS) requires systematic patient follow-up and
Table 2. TREAT decision support system [8]
Outcome Intervention Control Odds ratio p value
Appropriate antibiotics (ITT) 72.7% 64.5% 1.48 (CI 1.03–2.11) 0.033
Appropriate antibiotics (per protocola) 85.1% 64.5% 3.42 (CI 1.97–5.96) 0.001
Mean total antibiotic cost €565 €623 0.007
Mean LOS 8.83 days 9.45 days 0.055
Mortality (ITT) 12.9% 14.3% 0.93 (CI 0.73–1.19) NS
Mortality (per protocol) 9.7% 11.9% 0.90 (CI 0.58–1.39) NS
ITT, intention to treat; LOS, length of stay; NS, not signiﬁcant.
aPer-protocol analysis was performed including patients in intervention wards for whom physicians prescribed one of the
antibiotics from the three top-ranking treatments suggested by TREAT.
Davey and Marwick Inappropriate antimicrobial treatment 19
 2008 The Authors
Journal Compilation European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 3), 15–21
frequent collection of data on the occurrence of
the events of interest.
Another application of mathematical model-
ling is demonstrated by the work of Lipsitch et al.
[15]. They developed a multistate model of
bacterial transmission within a hospital that can
be used to study the effects of measures to control
nosocomial transmission and reduce antimicro-
bial resistance. In the model, subjects can move
from one state to another (e.g., infection with a
susceptible pathogen or no infection). The fact
that patients can move from one state to another,
both in the model and in real life, highlights the
need to follow patients and determine the time
when events of interest, such as acquiring a
resistant organism, occur.
INCREASING PATIENT AWARENESS
Appropriate antimicrobial treatment is no longer
a topic discussed only among infectious disease
specialists. Hospital-acquired infections and anti-
biotic resistance are frequently in the news, and
the public is becoming informed. An initiative to
increase patient awareness of healthcare-associ-
ated infections has been launched in the UK by
the National Concern for Healthcare Infections
(http://www.nc-hi.com). It began by providing
updated information on MRSA and expanded to
cover other resistant pathogens relevant to
hospital-acquired infections. The service now
includes a newsletter and information on
measures that a patient can take to reduce the
risk of acquiring an infection in the hospital
setting. The service also collects and disseminates
stories from patients who recount their experi-
ences and their interaction with the hospital
after a serious infection. Patient stories are a
very powerful way to inﬂuence policy-makers
and health service providers to take action to
improve patient safety. Examples can be found
on the WHO’s Patients for Patient Safety site
at http://www.who.int/patientsafety/patients_
for_patient/who_we_are/en/index.html.
The societal dimension of resistance is one
aspect of the BURDEN of Resistance and Disease
in European Nations project. The aim of this
initiative is to generate awareness and under-
standing among policy-makers and communities
at large to enable action to be taken on the
emergence and spread of antimicrobial resistance.
It will provide valid and comparable information
on the burden of disease and the costs attributable
to infections caused by antimicrobial-resistant
pathogens in European Union countries. As part
of the project, a descriptive study will be carried
out on experiences with, and outcomes of, infec-
tions caused by antimicrobial-resistant pathogens,
incorporating information from patients and ca-
rers. Another European project is Mastering
Hospital Antimicrobial Resistance (MOSAR). It
is examining factors determining the spread of
nosocomial pathogens in healthcare facilities and
in high-risk settings. It will also explore the
efﬁcacy and economic impact of control strate-
gies. It is anticipated that the resulting knowledge
will be disseminated to, and translated into,
improved patient care by carers and health
policy-makers.
CONCLUSION
Inappropriate treatment (i.e., using an agent to
which the pathogen is resistant) and delays in
effective treatment increase rates of morbidity
and mortality. Changing from inappropriate to
appropriate treatment once culture results have
become available can improve outcomes but not
to the same extent as initial appropriate antimi-
crobial treatment. Appreciation of patient risk is
important, as the likelihood of a poor outcome
with delayed appropriate therapy appears to be
greatest among critically ill patients, especially
those with high-risk sources of infection. Despite
the undoubted importance of inappropriate ther-
apy, it is but one of many factors that inﬂuence
clinical outcome, and should be considered in the
context of these other factors.
The economic impact of inappropriate therapy
extends beyond the costs attributable to morbidity
and mortality. Costs to a healthcare system
include those due to implementing isolation
procedures, changes to laboratory testing, and
education to improve infection control and anti-
microbial management. In evaluating the conse-
quences of inappropriate therapy, models should
consider infection as a time-dependent variable,
as failure to do so can lead to an inaccurate
estimate of the associated effects. The impact of
inappropriate therapy is likely to be better under-
stood with the development of models that
incorporate the time-dependency of events.
The consequences of antimicrobial resistance
can be particularly devastating for patients, their
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carers, and their families. Initiatives to increase
awareness of infection with resistant organisms
are underway in Europe. It is hoped that these
will help to better gauge the effects of antimicro-
bial resistance and identify strategies to better
tackle it.
REFERENCES
1. Luna CM, Vujacich P, Niederman MS et al. Impact of BAL
data on the therapy and outcome of ventilator-associated
pneumonia. Chest 1997; 111: 676–685.
2. Mosdell DM, Morris DM, Voltura A et al. Antibiotic treat-
ment for surgical peritonitis. Ann Surg 1991; 214: 543–549.
3. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH.
The inﬂuence of inadequate antimicrobial treatment of
bloodstream infections on patient outcomes in the ICU
setting. Chest 2000; 118: 146–155.
4. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Out-
comes analysis of delayed antibiotic treatment for hospi-
tal-acquired Staphylococcus aureus bacteremia. Clin Infect
Dis 2003; 36: 1418–1423.
5. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra
Z, Pitlik SD. The beneﬁt of appropriate empirical antibiotic
treatment in patients with bloodstream infection. J Intern
Med 1998; 244: 379–386.
6. Das I, Jumaa P. Has the severity of Clostridium difﬁcile
infections increased? J Hosp Infect 2007; 65: 85–86.
7. Heyland DK, Cook DJ, Grifﬁth L, Keenan SP, Brun-Buis-
son C. The attributable morbidity and mortality of venti-
lator-associated pneumonia in the critically ill patient. The
Canadian Critical Trials Group. Am J Respir Crit Care Med
1999; 159: 1249–1256.
8. Paul M, Andreassen S, Tacconelli E et al. Improving
empirical antibiotic treatment using TREAT, a computer-
ized decision support system: cluster randomized trial.
J Antimicrob Chemother 2006; 58: 1238–1245.
9. Howard D, Cordell R, McGowan JE Jr, Packard RM, Scott
RD 2nd, Solomon SL. Measuring the economic costs of
antimicrobial resistance in hospital settings: summary of
the Centers for Disease Control and Prevention-Emory
Workshop. Clin Infect Dis 2001; 33: 1573–1578.
10. McGowan JE Jr. Economic impact of antimicrobial resis-
tance. Emerg Infect Dis 2001; 7: 286–292.
11. Millar MR, Brown NM, Tobin GW, Murphy PJ, Windsor
AC, Speller DC. Outbreak of infection with penicillin-
resistant Streptococcus pneumoniae in a hospital for the
elderly. J Hosp Infect 1994; 27: 99–104.
12. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Out-
come and attributable mortality in critically ill patients
with bacteremia involving methicillin-susceptible and
methicillin-resistant Staphylococcus aureus. Arch Intern Med
2002; 162: 2229–2235.
13. Wangler M, Beyersmann J, Schumacher M. ChangeLOS:
an R-package for change in length of hospital stay based
on the Aalen–Johansen estimator. R News 2006; 6: 31–
35.
14. Beyersmann J, Gastmeier P, Grundmann H et al. Use of
multistate models to assess prolongation of intensive care
unit stay due to nosocomial infection. Infect Control Hosp
Epidemiol 2006; 27: 493–499.
15. Lipsitch M, Bergstrom CT, Levin BR. The epidemiology of
antibiotic resistance in hospitals: paradoxes and prescrip-
tions. Proc Natl Acad Sci USA 2000; 97: 1938–1943.
Davey and Marwick Inappropriate antimicrobial treatment 21
 2008 The Authors
Journal Compilation European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 3), 15–21
